<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168293">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076399</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-047</org_study_id>
    <secondary_id>2013-005452-15</secondary_id>
    <nct_id>NCT02076399</nct_id>
  </id_info>
  <brief_title>A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)</brief_title>
  <acronym>FIT</acronym>
  <official_title>A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fostamatinib is safe and effective  in the
      treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stable platelet response of at least 50,000/µL</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Stable platelet response by Week 24 defined as a platelet count of at least 50,000/µL on at least 4 of the 6 visits between Weeks 14-24.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Fostamatinib Disodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet PO bid (morning and evening) over the course of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib Disodium</intervention_name>
    <description>Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.</description>
    <arm_group_label>Fostamatinib Disodium</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
    <other_name>Fostamatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet PO bid (morning and evening) over the course of 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of persistent/chronic ITP for at least 3 months.

          -  Average platelet count &lt; 30,000/µL (and none &gt; 35,000 unless as a result of rescue
             therapy) from at least 3 qualifying counts

        Exclusion Criteria:

          -  Clinical diagnosis of autoimmune hemolytic anemia

          -  Uncontrolled or poorly controlled hypertension

          -  History of coagulopathy including prothrombotic conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Lowe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Lowe, MD</last_name>
    <phone>512-502-5353</phone>
    <email>alowe@rigel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Francis Medical Group Inc</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Boruchov, MD</last_name>
      <phone>860-714-4680</phone>
    </contact>
    <investigator>
      <last_name>Adam Boruchov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Boccia, MD</last_name>
      <phone>240-482-0526</phone>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent Immune Thrombocytopenic Purpura</keyword>
  <keyword>Chronic Immune Thrombocytopenic Purpura</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
